



# How to Plan and Conduct a Clinical Trial

Division of Research & Economic Development  
Lunch & Learn

**Bridget Koontz, MD FASTRO**

**Office of Clinical Research:**

**Sue Breno CCRC**

**Office of Sponsored Programs:**

**Cathy Harlan MPA GPC CRA**

**NSU** Florida


# TODAY'S OBJECTIVES

- Clinical Trials vs other types of Human Subject Research
- How Clinical Trials are supported at NSU
- What to do when considering conducting a human subject clinical trial
- What steps are required to open and conduct a clinical trial
- OCR services to guide and assist you through the study approval requirements



# WHAT IS A CLINICAL TRIAL?

A clinical trial is defined as a research study in which one or more human subjects are **prospectively** assigned to one or more **interventions** (which may include placebo or other control) to evaluate the effects of those interventions (*or diagnostics*) on **health**-related biomedical or behavioral **outcomes**.




# HUMAN SUBJECTS RESEARCH

“Research involving a living individual about whom data or biospecimens are obtained / used / studied / analyzed through interaction / intervention, or identifiable private information is used / studied / analyzed / generated.”

## Examples of human subjects research include:


- Collecting blood
- Administering medicine
- Collecting data
- Conducting a survey
- Interviewing
- Conducting a focus group
- Changing participants' environment
- Administering a psychological test
- Testing a new educational technique

“These interventions include drugs/small molecules/compounds; biologics; devices; procedures (e.g., surgical techniques); delivery systems (e.g., telemedicine, face-to-face interviews); strategies to change health-related behavior (e.g., diet, cognitive therapy, exercise, development of new habits); treatment strategies; prevention strategies; and diagnostic strategies.”



**Clinical Trials** are a subset of **Human Subjects Research**

# STAGES OF CLINICAL TRIALS



## Pre- Clinical Studies

- Lab projects
- Observational or cohort studies

## Pilot Study

- Feasibility of human testing

## Phase 1

- Safety “first in human”

## Phase 2

- Efficacy signal
- Side effects in larger study

## Phase 3

- Compare to standard of care

## Phase 4

- “post-approval” evaluation

# TYPES OF CLINICAL TRIALS

- **Intervention:** Drug, Device, Behavioral, Procedure
- **Whose Idea It Was:** Investigator-Initiated, Industry-developed
- **Who is Responsible for Trial:** Investigator-Sponsor vs Industry-Sponsor
- **Funding Source:** department/college, university, external non-profit or for-profit

# LIFECYCLE OF A CLINICAL TRIAL





# THE THREE “R”s OF RESEARCH AT NSU

**R**esources

**R**equirements

**R**esearch

# R esources

## College Resources

Dean  
Associate Dean for Research  
College IRB Representative  
College Business Representative  
College HR Representative  
Colleagues

## University Resources

Division of Research  
Institutional Review Board  
Research Pharmacy  
HPD Statistical Core  
Core Research Facilities  
INIM CLIA Lab

# R esources

## Division of Research and Economic Development

### Office of Sponsored Programs

Supports **non-profit funded**

- NIH, DOD
- State and county agencies
- Non-profit organizations
- HPD, President's

Cathy Harlan  
OSP@nova.edu

### Office of Clinical Research

Supports **industry funded**

- Trials
- Informed Consent and HIPAA  
Authorization review
- Data use agreements
- ClinicalTrials.gov resource

Susan Breno  
OCR@nova.edu

### Grant Writing Lab

Supports **concept development  
for faculty and staff**

- Finding opportunities
- Grant applications
- Grantsmanship trainings

Melanie Bauer  
GrantLab@nova.edu

### PRE-AWARD

- Finding funding opportunities
- Assisting with budget development
- Developing subcontracts
- Checking application requirements
- Completing university approvals / assurances
- Submitting (for several funding systems)

### POST-AWARD

- Processing contracts and subcontracts
- Award administration
- Ensuring compliance with sponsor rules
- Assisting with annual and final reports and continuation applications

Office of Clinical Research

Susan Breno  
Manager, OCR  
OCR@nova.edu

Supports **industry funded trials**  
both investigator or industry initiated

DEVELOPMENT

SUBMISSION

ACTIVATION

CLOSE



# R requirements

Pre-Award

Sponsor contacts PI or PI  
contacts External Funding Agency



Execute Confidential  
Disclosure Agreement

HOW? Contact OCR and include OCR in Industry communications

Until CDA signed, parties share limited information about the study

# R requirements

## Pre-Award

Sponsor contacts PI or PI  
contacts External Funding Agency

Execute Confidential  
Disclosure Agreement

Review Concept and/or  
Protocol, Budget

- Is there interest and feasibility?

For PI to consider: ability to enroll  
scientific interest  
competing studies active at NSU  
sufficient monetary support

# WHAT MAKES A PROTOCOL?

“Trial protocols are documents that **describe the objectives, design, methodology, statistical considerations** and aspects related to the organization of clinical trials. Trial protocols provide the **background and rationale** for conducting a study, highlighting specific research questions that are addressed, and taking into consideration ethical issues. Trial protocols must meet a standard that adheres to the principles of Good Clinical Practice, and are used to obtain ethics approval by local Ethics Committees or Institutional Review Boards.”

**\*\*Find TEMPLATE here: <https://www.nova.edu/irb/manual/forms/index.html>**

## Instructions:

Black font is required for all studies, *italicized blue font is optional depending on type of study.*

1. Title Page (Version Date)
  - a. Title
  - b. Date / Version #
  - c. College Association/Unit
  - d. PI and other key personnel – contact info and roles
  - e. *Funding source - if any*
    - i. *Contracted Services*
    - ii. *Subawards*
  - f. Site
    - i. On Campus Location
    - ii. Off-Campus Location
    - iii. Online
2. *Protocol Summary*  
*Brief description. (Similar to Abstract on grant.gov submission)*
3. Background / Aims
  - a. Purpose Statement
  - b. Objectives +/- Hypotheses
  - c. *Impact*
4. Study Design (including Basic Timeline)
  - a. Methodology
  - b. Schedule of Events
  - c. List of Data Collection instruments
5. Eligibility / Participant Population
  - a. If Retrospective:
    - i. How participants are identified
    - ii. Selection Criteria
  - b. If Prospective:
    - i. Inclusion/Exclusion criteria (*ie* eligibility)
    - ii. Screening (*ie* finding patients)
    - iii. Recruitment (*ie* presenting study)
    - iv. *Randomization*
6. Consent Process/Waiver of Consent, HIPAA Authorization

## Key Components to a Budget

Length of Study	Number of Subjects and Anticipated Enrollment Period Follow-Up Length
Institutional Overhead	Federal: 54%; Industry: 30%; Employee Fringe 25.75%*
Study Personnel	Calculating Effort: hours per subject AND hours per administrative activity
One Time Study Costs	Startup, annual, and close out activities Pharmacy, Lab, external admin fees Capital Equipment Presentation/Publication costs
Schedule of Events	What Happens at Each Visit and does study or insurance pay for that activity
Itemized Costs per Subject	For study activities, what will it cost to complete visit? Include testing, subject reimbursement/compensation

## Key Components to a Budget

Length of Study

Number of Subjects and Anticipated Enrollment Period  
Follow-Up Length

Institutional

**Work with College Business Representative**  
**Recommend using OCR template budget which will create**

25.75%\*

Study Period

**1) Funding Agency Budget**

activity

**2) Schedule of Events**

One Time

**3) a Banner Index budget**

**4) Benchmark Revenue and Expense Guidance**

Schedule

**\*\*IMPORTANT to budget every cost and study activity –  
common mistake is to underbudget**

Itemized Costs per Subject

For study activities, what will it cost to complete visit?  
Include testing, subject reimbursement/compensation



# FEASIBILITY CHECKLIST

OPTIONAL form to guide decision-making around feasibility of a study

- Enrollment Goal and Time Frame?
- Access to Suitable Subjects?
- Challenges to recruitment manageable?
- Any logistical challenges?
- How is data to be collected and shared?
- Adequate support?
- Any Research Ethics and Compliance issues?

## PROTOCOL FEASIBILITY ASSESSMENT CHECKLIST

Protocol Title: \_\_\_\_\_

Study Article(s): \_\_\_\_\_ Phase: \_\_\_\_\_

Therapeutic Area (Disease): \_\_\_\_\_

### 1. General

Does the protocol meet the research site's area of expertise?  Yes  No

Is the number of patients to be enrolled realistic for this site?  Yes  No

Number of subjects to be recruited by research site \_\_\_\_\_

Are the preparation time lines for this protocol realistic?  Yes  No

Is the enrolment period realistic for this site?  Yes  No

Do the inclusion/exclusion criteria fit with research site patient population?  Yes  No

Will we have to recruit subjects from outside?  Yes  No

Comments: \_\_\_\_\_

Will our IRB have problems with any aspects of this protocol?  Yes  No

Comments: \_\_\_\_\_

### 2. Procedures/clinical assessments

Are frequent observations/procedures required?  Yes  No

Comments: \_\_\_\_\_

Is the visit schedule flexible?  Yes  No

Comments: \_\_\_\_\_

# R requirements

## Pre-Award

Sponsor contacts PI or PI  
contacts External Funding Agency

Execute Confidential  
Disclosure Agreement

Review Concept and/or  
Protocol, Budget

- Is there interest and feasibility?

Sponsor: may schedule a Site Qualification Visit  
or may ask site to complete questionnaire  
to confirm expertise, resources, sufficient  
eligible population

# R requirements

## Pre-Award

Sponsor contacts PI or PI  
contacts External Funding Agency

Execute Confidential  
Disclosure Agreement

Review Concept and/or  
Protocol, Budget

Get Approval  
for Resources

- People, Space, Funding

# PROTOCOL APPROVAL RECORD

## Protocol Approval Record For Non-Federally Funded Human Subject Research

### INSTRUCTIONS

1. Complete Section I to determine whether this form is required.
2. **Complete this form prior to Clinical Trial Agreement negotiations.**
3. The Principal Investigator (PI) is responsible for the completion of this form, including **obtaining all personnel and Deans' signatures.**
4. Once completed, this form must be electronically forwarded to the Office of Clinical Research [ocr@nova.edu](mailto:ocr@nova.edu)

### Section I – Research Classification Questions

1. Is this a clinical trial?  No  Phase I  Phase II  Phase III  Phase IV

The NIH defines a clinical trial as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes (<http://grants.nih.gov/grants/glossary.htm>).

2. If it is not a clinical trial, please describe the type of study below.  
\_\_\_\_\_

3. Has this study already been registered on Clinicaltrials.gov?

No  Yes, NCT# \_\_\_\_\_

### SECTION II – Protocol

PI: \_\_\_\_\_

College / Center / Department \_\_\_\_\_

Phone ext. \_\_\_\_\_ Email \_\_\_\_\_ Cell phone \_\_\_\_\_

Protocol Title: \_\_\_\_\_

Proposed Start Date: \_\_\_\_\_ End Date: \_\_\_\_\_ Duration: \_\_\_\_ Year(s) / \_\_\_\_ Month(s)

Instrument of Award:  Contract  Sub-Contract

External Sponsor: \_\_\_\_\_

Address: \_\_\_\_\_

- 1) Must be completed by PI and signed by Dean
- 2) Includes key questions:
  - Type of award (contract or sub-contract) and contact info
  - Personnel effort requirements
  - Anticipated funding
  - Required NSU space and/or equipment
  - Possible conflicts of interest
- 3) Must be received by OCR to continue process

Find PAR here: <https://www.nova.edu/ocr/starting-points.html>

# R requirements

## Pre-Award

Sponsor contacts PI or PI  
contacts External Funding Agency

Execute Confidential  
Disclosure Agreement

Review Concept and/or  
Protocol, Budget

Get Approval  
for Resources


Execute Legal  
Agreements



# CLINICAL TRIAL AGREEMENT

- Agrees to responsibilities of each Party regarding execution of study
- Negotiated by DoR and Funding Source
  - Katherine Rose, JD LLM AVP/Attorney
- PIs cannot sign for NSU – must be DOR
- Must include finalized budget, protocol, informed consent form
- Other Legal Agreements: Sub-contract, Ancillary Site, Material Transfer, Data Use Agreements


Legal Agreement between NSU and Funding Source



# CLINICAL TRIAL AGREEMENT

- Agrees to responsibilities of each Party regarding execution of study
- Negotiated by DoR and Funding Source
  - Katherine Rose, JD LLM AVP/Attorney
- PIs cannot sign for NSU – must be DOR
- Must include finalized budget, protocol, informed consent form
- Other Legal Agreements: Sub-contract, Ancillary Site, Material Transfer, Data Use Agreements

Legal Agreement between NSU and Funding Source



PI can complete concurrently

IND Submission\*

COI Screening

IRB Submission

Liability Coverage Review

ClinicalTrials.gov registration

\*IND submission IF Investigator is also Sponsor

# IS AN IND OR IDE REQUIRED? WHOSE RESPONSIBILITY?

Sometimes Investigational New Drug / Investigational Device Exemption is required

An IND / IDE application is a request to the FDA for authorization to use an investigational drug/device in human studies. The investigational product can be pre-approval or for a different indication than already approved.

Typically whomever conceives of and designs trial will be sponsor and hold IND / IDE

**IND and IDE discussions need DOR consultation**



# NSU INSTITUTIONAL REVIEW BOARD (IRB)

<https://www.nova.edu/irb>

IRB approval is mandated prior to the initiation of any human subjects study activity.

\*\*Chart reviews for potential subjects requires a Review Preparatory to Research approval

IRB reviews and approves:

- Initial Research Protocol
- Amendments (including any personnel changes)
- Annual Continuing Reviews
- Closing Report
- SAE Reporting
- Subject Instructions
- Recruitment Materials

## Other necessary forms: HIPAA Authorization for Research

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) is a federal law that required the creation of national standards to protect sensitive patient health information from being disclosed without the patient's consent or knowledge.

# SUBMITTING TO THE IRB

- Electronic Submission system: <https://www.nova.edu/irb/irbmanager/index.html>
- You will need:
  - Protocol, ICF, Delegation Log, Training Documentation
  - Any Participant facing communications (Recruitment materials count!)

## Training:

- Free and available on CITI (<https://www.nova.edu/irb/training.html>)
- NSU HIPAA Privacy Training (<https://www.nova.edu/hipaa-privacy/training/course.html>)

# NSU REQUIRED TRAINING FOR CLINICAL TRIALS

## Through CITI:

- Required: Human Subjects Research (either “group 1: Biomedical (HPD) Researchers” or Group 2: Social-Behavioral-Educational (Non-HPD) Researchers”
- CITI Good Clinical Practice Course (for PIs and certain personnel)\*

## Through NSU:

- NSU HIPAA Training
- request through Privacy Office Luann Healy  
[LHealy@nova.edu](mailto:LHealy@nova.edu)



[My Courses](#)

[My Records](#)

[My CE/CMEs](#)

[Support](#)

Welcome, Bridget

[Add Institutional Affiliation](#)  
[Register as Independent Learner](#)

26

Courses Completed

15

Years of Membership

Courses Ready to Begin

[Learner Tools](#)

Nova Southeastern University

CITI Good Clinical Practice Course

Stage 1 - Basic Course

\*See policy OCR-2 here: <https://www.nova.edu/ocr/policies-for-gcp/administrative-policies.html>

**NSU** Florida

---

## LIABILITY COVERAGE REVIEW

To document that compensation to subject(s) for trial-related injury will be available

OCR will submit protocol synopsis to NSU's insurance carrier

Protects all parties involved



# REGISTERING ON CLINICALTRIALS.GOV

ClinicalTrials.gov is a databank or registry of federally funded, privately supported, and unfunded clinical trials involving human subjects.

... is the result of a federal law requiring that clinical trials be registered to improve public access to information about clinical research, promote public trust in research and inform future research. Medical journals also require prospective registration of trials to be considered for publications.

NSU requires that ANY clinical trial in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control or diagnostics) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.\*

→ Request a ClinicalTrials.gov User ID from OCR

\*See policy OCR-1 here: <https://www.nova.edu/ocr/policies-for-gcp/administrative-policies.html> 



---

# CONGRATULATIONS!!


## Responsibilities of PI:

- is responsible for the safe and ethical conduct of the study and the quality and accuracy of the data
- ensures the study is performed according to the protocol and all applicable regulations
- is responsible for the safety of subjects enrolled on the study and for reporting of any safety events per protocol and regulations
- conducts, directs, or supervises research involving human participants to make certain that the research is consistent with NSU policies and procedures, and that the appropriate IRB has been informed of existing knowledge of any risks involved.
- report real or potential conflicts of interests with the annual COI survey and at any time a new COI relationship is made.



# R requirements


## Activation Process



# SETTING UP A RESEARCH ACCOUNT IN BANNER

OSP or OCR must send in request including:

- 1) Finance “New Account Request”
- 2) Project Summary “Digest”
- 3) Executed CTA
- 4) IRB approval
- 5) Approved Budget in Banner format
- 6) List of Approved Personnel for Index Access  
(Pls: work with OCR/OSP to create this list)



# R requirements

## Activation Process

Banner Index Creation



Study Start-Up Meeting (NOT the SAME as SIV)

### Regulatory Requirements:

- Regulatory Binder
- Accountability and Processes for Investigational Agents
- ClinicalTrials.gov – must be registered within 21 days of first subject; requires updates annually or with status change

Key People to include in Study Start-Up: Contracts & Grants Accounting Accountant assigned  
College Business and HR Representatives  
Pharmacy and/or Lab Leadership  
NSU Health Billing Manager (Patient Financial Services)

# R requirements

## Activation Process

Banner Index Creation

Study Start-Up Meeting

PFS Billing Grid\*

\*Required if any Standard of Care billing potential


In Schedule of Events, PI **must** itemize which activities are billed to research and which are billed to insurance/patient

**CRITICAL COMPLIANCE STEP TO PREVENT FRAUD**

**HOW: Contact Patient Financial Services**

# R requirements


## Activation Process



Effort needs to match contract  
eCert tracks all effort billed directly on research-tagged Indexes

# R requirements

## Activation Process



# R esearch




Enroll and Perform Study Activities



Regular Financial Reconciliation



Be Prepared for Audits



File IRB Amendments and Annual Reports



Study Close-Out



# COMPLIANCE WITH REGULATORY REQUIREMENTS FOR STUDY CONDUCT

Filing of all IRB communications

Adverse Event reporting

Protocol Deviations reporting

PI review of IND Safety reports  
(external sites)

- MedWatch reports

Data Safety Monitoring Board

Financial Conflict of Interest  
Updates

Infectious Substances Packaging and  
Shipping Training

Investigational Drug/Device  
Accountability

Biosafety - the prevention of large-scale  
loss of biological integrity

- Back up power in case of loss of  
electricity

# R esearch

## Open Trial

Enroll and Perform Study Activities



Regular Financial Reconciliation

Meet with CGA accountant and College Business Representative to review Index, Invoices, Revenue, and Expenses



Be Prepared for Audits

Create a Regulatory Binder with all trial documentation



File IRB Amendments and Annual Reports



Study Close-Out

# STUDY CLOSE-OUT

**When ALL study activities are complete and ALL revenue received**

- Submit all data to Sponsor
- Correct any final Sponsor generated queries
- Review Regulatory Binder
  - missing documents
  - current credentials are filed
- Close IRB
- Update ClinicalTrials.gov
- Reconcile and close Banner Index



# DATA MANAGEMENT AND STORAGE

Sponsor will have requirements for maintenance of onsite access to study records after study closure. In absence of other guidance, NSU policy is to retain documents onsite for three years.

The longest most distant date shall be used as the destruction date. Per 21CFR312.62 **An investigator shall retain records required to be maintained under this part for a period of 2 years following the date a marketing application is approved for the drug for the indication for which it is being investigated; or, if no application is to be filed or if the application is not approved for such indication, until 2 years after the investigation is discontinued and FDA is notified OR its relevant successor or equivalent for non-drug studies OR the timeframe specified by the sponsor contractually, whichever is longer.**

→ When ready to archive in long term storage, contact:

NSU Records Management <https://www.nova.edu/records/index.html>



**NSU** Florida

**Questions?**

Division of Research: 954-262-7509

[OCR@nova.edu](mailto:OCR@nova.edu)